drugset / Trial / NCT00523042

Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma

NCT00523042

Phase 3 Terminated 10 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe, Asia, Oceania and the United States of America (USA). This is a one-year clinical trial to compare the safety of inhaled preprandial human insulin to subcutaneous insulin aspart in subjects with type 1 or 2 diabetes and asthma.

Timeline

Start
2007-08-30
Primary completion
2008-02-28
Completion
2008-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic Inhaled
Comparator insulin aspart Protein / enzyme biologic Subcutaneous